Abeona Therapeutics Inc (NASDAQ:ABEO) shares, rose in value on Friday, March 07, with the stock price down by -2.64% to the previous day’s close as strong demand from buyers drove the stock to $5.16.
Actively observing the price movement in the last trading, the stock closed the session at $5.30. Referring to stock’s 52-week performance, its high was $8.87, and the low was $3.05. On the whole, ABEO has fluctuated by -12.24% over the past month.
With the market capitalization of Abeona Therapeutics Inc currently standing at about $224.31 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 83.33k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ABEO’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ABEO currently trading nearly -6.84% and -7.10% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.64, while the 7-day volatility ratio is showing 6.82% which for the 30-day chart, stands at 5.05%. Furthermore, Abeona Therapeutics Inc (ABEO)’s beta value is 1.68, and its average true range (ATR) is 0.28.
A comparison of Abeona Therapeutics Inc (ABEO) with its peers suggests the former has fared considerably weaker in the market. ABEO showed an intraday change of -2.64% in last session, and over the past year, it shrunk by -39.01%%.
Data on historical trading for Abeona Therapeutics Inc (NASDAQ:ABEO) indicates that the trading volumes over the past 3 months, they’ve averaged 264.79K. According to company’s latest data on outstanding shares, there are 43.40 million shares outstanding.
Nearly 11.70% of Abeona Therapeutics Inc’s shares belong to company insiders and institutional investors own 71.71% of the company’s shares. The stock has fallen by -7.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABEO stock heading into the next quarter.
